How do we treat cutaneous T-cell lymphoma?

Lymphoma
17/09/2020

G Ital Dermatol Venereol. 2020 Sep 17. doi: 10.23736/S0392-0488.20.06606-7. Online ahead of print.

ABSTRACT

Cutaneous T-cell lymphomas are a heterogeneous group of non-Hodgkin lymphoma which is based on the malignant proliferation of skin-related T lymphocytes. The clinical appearance, as well as the course and the associated therapeutic approach, are sometimes very different between the different subtypes. Since allogeneic stem cell transplantation is currently the only curative option, and the morbidity and mortality are not insignificant, a therapy concept should be developed that takes into


account its often rather indolent but chronic course. This concept should enable a good disease control with as few side effects as possible and preserve or improve the quality of life. In the early stages of the disease, skin-oriented therapies are generally used first before systemic and increasingly aggressive therapeutic agents are used as the disease progresses. Taking into account the current guidelines, literature and subjective experience, we summarise in this review how we treat cutaneous T-cell lymphomas.